Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15881635 | 0.88 | ALDH1A1 (0.55) | ALDH1A1 | |
| SCHEMBL17335563 | 0.85 | EPHX2 (0.77) | ALDH1A1 | |
| SCHEMBL23417918 | 0.85 | ALDH1A1 (0.58) | ALDH1A1 | |
| SCHEMBL1456923 | 0.83 | P2RX7 (0.49) | — | |
| SCHEMBL1456919 | 0.83 | P2RX7 (0.49) | — | |
| SCHEMBL31036978 | 0.83 | P2RX7 (0.49) | — | |
| SCHEMBL17205705 | 0.81 | CYP1A2 (0.71) | ALDH1A1 | |
| SCHEMBL25558429 | 0.80 | MMP13 (0.46) | — | |
| SCHEMBL23417762 | 0.80 | TRPV1 (0.51) | — | |
| SCHEMBL30613373 | 0.79 | SMN1; SMN2 (0.67) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945929-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-11-25 | — | — | EP | claimed |
| WO-2014111113-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-07-24 | — | — | WO | claimed |
| WO-2022246086-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| EP-2945929-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014111113-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | ALDH1A1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.